

# ePrescribing Outcomes



## RESULTS OF PILOT SITES TESTING

Rochelle Woolley, MPH, MS  
Woolley & Associates  
NORC Contractor Evaluator

# Focus of Testing

2

Each of the five grantees were...

- required to test all six initial standards
- given flexibility to test and report on other outcomes of eprescribing
- able to include a wide range of participants including prescribers, pharmacies, technology vendors.

# ePrescribing Outcomes Tested by Pilots

3

- Prescriber uptake & satisfaction
- Workflow changes
- Impact on callbacks between providers, pharmacies, and PBMs/payers
- Impact on e-Prescribing features & functions
- Effect on medication errors

# It's Not Just About Standards

4

- Use of common standards is key to interoperability
- Need for technological architecture that supports common standards
- Shared commitment, policies, business rules and a culture of trust and collaboration
- Addressing the challenges and overcoming current obstacles will drive adoption


# Medication History

5

- Adoption rate is lower than desired
- Flexibility in standard regarding “*optional*” data fields
- Poor integration into eprescribing workflow
- Lack of knowledge or education on how to use this feature
- Standardization lacking on presentation and how to reconcile lists from multiple sources

## RAND model of the ePrescribing Process

One hope for eprescribing is that it would improve workflow for **both** prescribers and pharmacists. In order to promote widespread adoption of eprescribing, both prescribers and pharmacists realize that modifications in current workflow will need to be embraced for achieving the true benefits.



# Change in Workflow is Critical

7

- Improvements in workflow must impact both prescribers and pharmacists
- Measurement of success can only be assessed with true end-to-end eprescribing
- Key learning's from the pilots demonstrate adoption is based on the high use of surrogate prescribers
- Critical need for training, education, and understanding of key value propositions for **both** prescribers and pharmacists

# Just the Beginning

8

- What we've seen reported thus far is only preliminary results.
- Additional data analysis is needed to draw more rigorous conclusions.
- We're at a turning point, yet not at the finish line yet.
- Recommendations going forward should support ongoing training and education of *all* key stakeholders in the prescribing process.